Free Trial Information
BioCentury | Nov 14, 2005
Clinical News

Coramsine regulatory update

...Orphan Drug designation to Coramsine, a solasodine glycoside, to treat metastatic renal cell carcinoma (RCC). Solbec...
Read More
BioCentury | Oct 31, 2005
Clinical News

Coramsine: Phase II start

...trial will be conducted in Australia and the U.S. and will enroll about 40 patients. Solbec...
Read More
BioCentury | Oct 24, 2005
Clinical News

Solbec Pharmaceuticals Ltd preclinical data

...had complete regression and all 6 were immune to tumor regrowth when rechallenged with mesothelioma. Solbec...
Read More
BioCentury | Oct 17, 2005
Company News

Solbec management update

Solbec Pharmaceuticals Ltd. (ASX:SBP), Osborne Park, Australia Business: Cancer, Autoimmune Hired: Graeme Howie as an executive director, retired as a team leader of Endocrinology at Pfizer Inc. Resigned: Stephen Carter as managing director WIR Staff...
Read More
BioCentury | Sep 12, 2005
Clinical News

Coramsine: Phase I data

...patients who completed the trial had a tumor response with 1 longer term durable response. Solbec...
Read More
BioCentury | Aug 8, 2005
Clinical News

Solbec Pharmaceuticals Ltd preclinical data

...immune when re-inoculated with cancer and the other died as a result of Coramsine overdose. Solbec...
Read More
BioCentury | May 16, 2005
Finance

Taking the ADR route

...Taking the ADR route Company Exchange Symbol Country Depositary bank (A) Date Solbec OTC SLBPY Australia...
Read More
BioCentury | Apr 7, 2003
Company News

Solbec board of directors update

Solbec Pharmaceuticals Ltd. (ASX:SBP), Nedlands, Australia Business: Cancer, Metabolic Appointed: Anthony Kiernan, an industry consultant, as chairman; and Michael Grant, stockbroker at Bell Potter Resigned: Michael Ruane WIR Staff...
Read More
Items per page:
1 - 8 of 8
BioCentury | Nov 14, 2005
Clinical News

Coramsine regulatory update

...Orphan Drug designation to Coramsine, a solasodine glycoside, to treat metastatic renal cell carcinoma (RCC). Solbec...
Read More
BioCentury | Oct 31, 2005
Clinical News

Coramsine: Phase II start

...trial will be conducted in Australia and the U.S. and will enroll about 40 patients. Solbec...
Read More
BioCentury | Oct 24, 2005
Clinical News

Solbec Pharmaceuticals Ltd preclinical data

...had complete regression and all 6 were immune to tumor regrowth when rechallenged with mesothelioma. Solbec...
Read More
BioCentury | Oct 17, 2005
Company News

Solbec management update

Solbec Pharmaceuticals Ltd. (ASX:SBP), Osborne Park, Australia Business: Cancer, Autoimmune Hired: Graeme Howie as an executive director, retired as a team leader of Endocrinology at Pfizer Inc. Resigned: Stephen Carter as managing director WIR Staff...
Read More
BioCentury | Sep 12, 2005
Clinical News

Coramsine: Phase I data

...patients who completed the trial had a tumor response with 1 longer term durable response. Solbec...
Read More
BioCentury | Aug 8, 2005
Clinical News

Solbec Pharmaceuticals Ltd preclinical data

...immune when re-inoculated with cancer and the other died as a result of Coramsine overdose. Solbec...
Read More
BioCentury | May 16, 2005
Finance

Taking the ADR route

...Taking the ADR route Company Exchange Symbol Country Depositary bank (A) Date Solbec OTC SLBPY Australia...
Read More
BioCentury | Apr 7, 2003
Company News

Solbec board of directors update

Solbec Pharmaceuticals Ltd. (ASX:SBP), Nedlands, Australia Business: Cancer, Metabolic Appointed: Anthony Kiernan, an industry consultant, as chairman; and Michael Grant, stockbroker at Bell Potter Resigned: Michael Ruane WIR Staff...
Read More
Items per page:
1 - 8 of 8